181 related articles for article (PubMed ID: 9815816)
21. Growth inhibitory effects of 1alpha, 25-dihydroxyvitamin D(3) are mediated by increased levels of p21 in the prostatic carcinoma cell line ALVA-31.
Moffatt KA; Johannes WU; Hedlund TE; Miller GJ
Cancer Res; 2001 Oct; 61(19):7122-9. PubMed ID: 11585744
[TBL] [Abstract][Full Text] [Related]
22. Synthetic analogs of vitamin D3 have inhibitory effects on breast cancer cell lines.
Fioravanti L; Miodini P; Cappelletti V; DiFronzo G
Anticancer Res; 1998; 18(3A):1703-8. PubMed ID: 9673393
[TBL] [Abstract][Full Text] [Related]
23. 1alpha,25-Dihydroxyvitamin D3-3beta-(2)-bromoacetate, an affinity labeling derivative of 1alpha,25-dihydroxyvitamin D3 displays strong antiproliferative and cytotoxic behavior in prostate cancer cells.
Swamy N; Persons KS; Chen TC; Ray R
J Cell Biochem; 2003 Aug; 89(5):909-16. PubMed ID: 12874825
[TBL] [Abstract][Full Text] [Related]
24. Apoptosis induced by vitamin D compounds in breast cancer cells is inhibited by Bcl-2 but does not involve known caspases or p53.
Mathiasen IS; Lademann U; Jäättelä M
Cancer Res; 1999 Oct; 59(19):4848-56. PubMed ID: 10519395
[TBL] [Abstract][Full Text] [Related]
25. 19-nor-hexafluoride analogue of vitamin D3: a novel class of potent inhibitors of proliferation of human breast cell lines.
Koike M; Elstner E; Campbell MJ; Asou H; Uskokovic M; Tsuruoka N; Koeffler HP
Cancer Res; 1997 Oct; 57(20):4545-50. PubMed ID: 9377567
[TBL] [Abstract][Full Text] [Related]
26. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
Igawa T; Lin FF; Rao P; Lin MF
Prostate; 2003 Jun; 55(4):247-58. PubMed ID: 12712404
[TBL] [Abstract][Full Text] [Related]
27. Biological effects of 1alpha-hydroxy- and 1beta-(hydroxymethyl)-vitamin D compounds relevant for potential colorectal cancer therapy.
Hofer H; Ho Gm; Peterlik M; Uskokovic MR; Lee JK; White MC; Posner GH; Cross HS
J Pharmacol Exp Ther; 1999 Nov; 291(2):450-5. PubMed ID: 10525058
[TBL] [Abstract][Full Text] [Related]
28. Antiproliferative activity in vitro of side-chain analogues of calcitriol against various human normal and cancer cell lines.
Opolski A; Wietrzyk J; Chrobak A; Marcinkowska E; Wojdat E; Kutner A; Radzikowski C
Anticancer Res; 1999; 19(6B):5217-22. PubMed ID: 10697538
[TBL] [Abstract][Full Text] [Related]
29. Vitamins as hormones.
Reichrath J; Lehmann B; Carlberg C; Varani J; Zouboulis CC
Horm Metab Res; 2007 Feb; 39(2):71-84. PubMed ID: 17326003
[TBL] [Abstract][Full Text] [Related]
30. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
Murthy S; Agoulnik IU; Weigel NL
Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
[TBL] [Abstract][Full Text] [Related]
31. Increased expression of corepressors in aggressive androgen-independent prostate cancer cells results in loss of 1alpha,25-dihydroxyvitamin D3 responsiveness.
Ting HJ; Bao BY; Reeder JE; Messing EM; Lee YF
Mol Cancer Res; 2007 Sep; 5(9):967-80. PubMed ID: 17855664
[TBL] [Abstract][Full Text] [Related]
32. Gene profiling and promoter reporter assays: novel tools for comparing the biological effects of botanical extracts on human prostate cancer cells and understanding their mechanisms of action.
Bigler D; Gulding KM; Dann R; Sheabar FZ; Conaway MR; Theodorescu D
Oncogene; 2003 Feb; 22(8):1261-72. PubMed ID: 12606954
[TBL] [Abstract][Full Text] [Related]
33. 25-Hydroxyvitamin D3, the prohormone of 1,25-dihydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells.
Barreto AM; Schwartz GG; Woodruff R; Cramer SD
Cancer Epidemiol Biomarkers Prev; 2000 Mar; 9(3):265-70. PubMed ID: 10750664
[TBL] [Abstract][Full Text] [Related]
34. Evidence for tissue- and cell-type selective activation of the vitamin D receptor by Ro-26-9228, a noncalcemic analog of vitamin D3.
Peleg S; Ismail A; Uskokovic MR; Avnur Z
J Cell Biochem; 2003 Feb; 88(2):267-73. PubMed ID: 12520525
[TBL] [Abstract][Full Text] [Related]
35. Regulation of prostate-specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide.
Rekasi Z; Schally AV; Plonowski A; Czompoly T; Csernus B; Varga JL
Prostate; 2001 Aug; 48(3):188-99. PubMed ID: 11494334
[TBL] [Abstract][Full Text] [Related]
36. Autocrine TGFbeta signaling mediates vitamin D3 analog-induced growth inhibition in breast cells.
Yang L; Yang J; Venkateswarlu S; Ko T; Brattain MG
J Cell Physiol; 2001 Sep; 188(3):383-93. PubMed ID: 11473365
[TBL] [Abstract][Full Text] [Related]
37. Effect of calcitriol on prostate-specific antigen in vitro and in humans.
Beer TM; Garzotto M; Park B; Mori M; Myrthue A; Janeba N; Sauer D; Eilers K
Clin Cancer Res; 2006 May; 12(9):2812-6. PubMed ID: 16675575
[TBL] [Abstract][Full Text] [Related]
38. 5,6-trans-16-ene-vitamin D3: a new class of potent inhibitors of proliferation of prostate, breast, and myeloid leukemic cells.
Hisatake J; Kubota T; Hisatake Y; Uskokovic M; Tomoyasu S; Koeffler HP
Cancer Res; 1999 Aug; 59(16):4023-9. PubMed ID: 10463602
[TBL] [Abstract][Full Text] [Related]
39. 1,25-Dihydroxy-16-ene-23-yne-vitamin D3 and prostate cancer cell proliferation in vivo.
Schwartz GG; Hill CC; Oeler TA; Becich MJ; Bahnson RR
Urology; 1995 Sep; 46(3):365-9. PubMed ID: 7660511
[TBL] [Abstract][Full Text] [Related]
40. Vitamin D3 analogues.
Kragballe K
Dermatol Clin; 1995 Oct; 13(4):835-9. PubMed ID: 8785887
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
